Table 3.

Lung nodule malignancy prediction diagnostic test performance

Description	No. of patients	Sensitivity (%)	Specificity (%)
Plasma ctDNA and FFPE	192	91	88
ctDNA mutation (average of all stages)	192	68	96
Stage I lung cancer	87	63	96
Stage II lung cancer	29	83	96
Stage III lung cancer	17	94	96
Panel of six serum biomarkers (BMs)	175	51	83
LDA model of ctDNA and BMs (all stages)	174	80	99

ctDNA. circulating tumour DNA; FFPE, formalin fixed paraffin embedded; LDA, linear discriminant analysis.